<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37773871</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>39</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Progressive multifocal leukoencephalopathy without overt immunosuppression.</ArticleTitle><Pagination><StartPage>e35265</StartPage><MedlinePgn>e35265</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e35265</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000035265</ELocationID><Abstract><AbstractText>Progressive multifocal leukoencephalopathy (PML) is a central nervous system disease caused by the human polyomavirus 2 that usually occurs in a setting of immunodeficiency. PML without overt immunosuppression is considered a rare occurrence but has been described in multiple previous case reports and series. Its prevalence, overall frequency, and prognosis are largely unknown. This is a single-center retrospective review of all University of Florida cases with the ICD10 PML diagnosis code (A81.2). PML without overt immunosuppression was defined as absence of human immunodeficiency virus (HIV) infection, hematological malignancy, immunomodulatory/-suppressive medications, autoimmune conditions with a propensity for PML (sarcoidosis, systemic lupus erythematosus). Cases that did not fulfill criteria for clinically or histologically definite PML were excluded. Of 52 patients with the ICD10 code A 81.2, 17 fulfilled definite diagnostic criteria for PML. Overt immunosuppression was identified in 15/17 (88.2%) cases (10/17 (58.8%): human immunodeficiency virus; 5/17 (29.4%): immunomodulatory/-suppressive medication). Two/seventeen (11.8%) cases were consistent with PML without overt immunosuppression. Possible contributing factors were a preceding dog bite and mild hypogammaglobulinemia M (39&#x2009;mg/dL) in case 1 and significant alcohol use without evidence for liver disease in case 2. Both cases were fatal within 6 (case 1) and 2 (case 2) months. The results suggest that PML without overt immunosuppression may be more common than previously described. Therefore, PML should be considered even in the absence of overt immunosuppression if clinical and radiographic findings are suggestive of the diagnosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Varun</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Branstetter</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savaram</LastName><ForeName>Srikar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasquez</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swords</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghili-Mehrizi</LastName><ForeName>Sina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Zengotita</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montalvo</LastName><ForeName>Mayra</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuquilin</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Addie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rempe</LastName><ForeName>Torge</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0538-1378</Identifier><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007968" MajorTopicYN="Y">Leukoencephalopathy, Progressive Multifocal</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>15</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37773871</ArticleId><ArticleId IdType="pmc">PMC10545270</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000035265</ArticleId><ArticleId IdType="pii">00005792-202309290-00089</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bartsch T, Rempe T, Leypoldt F, et al. . The spectrum of progressive multifocal leukoencephalopathy: a practical approach. Eur J Neurol. 2019;26:566&#x2013;e41.</Citation><ArticleIdList><ArticleId IdType="pubmed">30629326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch T, Rempe T, Wrede A, et al. . Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol. 2015;78:501&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4926166</ArticleId><ArticleId IdType="pubmed">26150206</ArticleId></ArticleIdList></Reference><Reference><Citation>Boziki M, Metallidis S, Habidou E, et al. . Progressive multifocal leukoencephalopathy in an elderly immunocompetent-appearing patient: Relevance with L-selectin (CD62L) expression and immunosenescence. Clin Neurol Neurosurg. 2021;205:106625.</Citation><ArticleIdList><ArticleId IdType="pubmed">33892220</ArticleId></ArticleIdList></Reference><Reference><Citation>Christakis PG, Okin D, Huttner AJ, et al. . Progressive multifocal leukoencephalopathy in an immunocompetent patient. J Neurol Sci. 2013;326:107&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">23375959</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheuens S, Pierone G, Peeters P, et al. . Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. 2010;81:247&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889486</ArticleId><ArticleId IdType="pubmed">19828476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourineni VC, Juvet T, Kumar Y, et al. . Progressive multifocal leukoencephalopathy in a 62-year-old immunocompetent woman. Case Rep Neurol Med. 2014;2014:549271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965952</ArticleId><ArticleId IdType="pubmed">24711940</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal J, Dalal P, Bowman M, et al. . Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. J Neurovirol. 2016;22:683&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27273076</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen KK, Torp SH, Rydland J, et al. . Progressive multifocal leukoencephalopathy in an immunocompetent patient? Case Rep Neurol. 2013;5:149&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806704</ArticleId><ArticleId IdType="pubmed">24163670</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebowitz JE, Zeiger W, Sotirchos E, Pardo-Villamizar C. An unusual case of progressive multifocal leukoencephalopathy in a patient with non-traditional risk factors. J Neurol Disord. 2015;3:247.</Citation></Reference><Reference><Citation>Nanda T. Progressive multifocal leukoencephalopathy in a HIV negative, immunocompetent patient. Case Rep Neurol Med. 2016;2016:7050613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978838</ArticleId><ArticleId IdType="pubmed">27529042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriwastava S, Khan E, Khalid SH, et al. . Progressive multifocal leukoencephalopathy in an immunocompetent patient: a case report and review of literature. J Med Virol. 2022;94:2860&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34854099</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan IL, Koralnik IJ, Rumbaugh JA, et al. . Progressive multifocal leukoencephalopathy in a patient without immunodeficiency. Neurology. 2011;77:297&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136053</ArticleId><ArticleId IdType="pubmed">21734181</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaklavas C, Sotelo-Rafiq EP, Lovy J, et al. . Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J. 2010;7:256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2954859</ArticleId><ArticleId IdType="pubmed">20920200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucker BE, Stacpoole SRL. Progressive multifocal leukoencephalopathy in the absence of immunosuppression. J Neurovirol. 2018;24:119&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790842</ArticleId><ArticleId IdType="pubmed">29139004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YY, Lan MY, Peng CH, et al. . Progressive multifocal leukoencephalopathy in an immunocompetent Taiwanese patient. J Formos Med Assoc. 2007;106:S60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17493899</ArticleId></ArticleIdList></Reference><Reference><Citation>Naess H, Glad S, Storstein A, et al. . Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol. 2010;10:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880963</ArticleId><ArticleId IdType="pubmed">20482768</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Patel J, Ikwuagwu J. Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother. 2010;65:2489&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961908</ArticleId></ArticleIdList></Reference><Reference><Citation>Puri V, Chaudhry N, Gulati P, et al. . Progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+T lymphocytopenia. Neurol India. 2010;58:118&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20228479</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney F, Fernandez D, Harrington H. Progressive multifocal leucoencephalopathy in a patient with idiopathic CD4+ lymphocytopenia. Ir Med J. 2012;105:84&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22558816</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Alvarado M, Sedano MJ, Gonzalez-Quintanilla V, et al. . Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci. 2013;327:75&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23465508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastrup O, Goricke S, Kretzschmar H, et al. . Progressive multifocal leukoencephalopathy of the brainstem in an immunocompetent patient--JC and BK polyoma-virus coinfection? A case report and review of the literature. Clin Neurol Neurosurg. 2013;115:2390&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">24094671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Z, Akaza M, Numasawa Y, et al. . Failure of mefloquine therapy in progressive multifocal leukoencephalopathy: report of two Japanese patients without human immunodeficiency virus infection. J Neurol Sci. 2013;324:190&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23182496</ArticleId></ArticleIdList></Reference><Reference><Citation>Alstadhaug KB, Croughs T, Henriksen S, et al. . Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol. 2014;71:1030&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979548</ArticleId></ArticleIdList></Reference><Reference><Citation>Izaki S, Tanaka S, Tajima T, et al. . [A case of cerebellar brainstem form of progressive multifocal leukoencephalopathy associated with idiopathic CD4+ lymphocytopenia]. Rinsho shinkeigaku. 2015;55:345&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26028198</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kolk NM, Arts P, van Uden IW, et al. . Progressive multifocal leukoencephalopathy in an immunocompetent patient. Ann Clin Transl Neurol. 2016;3:226&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774259</ArticleId><ArticleId IdType="pubmed">27042682</ArticleId></ArticleIdList></Reference><Reference><Citation>Aotsuka Y, Uzawa A, Nishimura K, et al. . Progressive multifocal leukoencephalopathy localized in the cerebellum and brainstem associated with idiopathic CD4(+) T lymphocytopenia. Intern Med. 2016;55:1645&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27301521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet A, Kerbrat A, Tattevin P, et al. . Progressive multifocal leukoencephalopathy in a patient with silicosis. J Neurol. 2016;263:1866&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27416854</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta HV, Gokden M, Ramakrishnaiah RH, et al. . Progressive multifocal leukoencephalopathy mimicking glioma in a patient with idiopathic CD4 lymphocytopenia. Acta Neurol Belg. 2016;116:391&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26319126</ArticleId></ArticleIdList></Reference><Reference><Citation>Miskin DP, Chalkias SG, Dang X, et al. . Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia. Neurol Neuroimmunol Neuroinflam. 2016;3:e213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4841501</ArticleId><ArticleId IdType="pubmed">27144212</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghoram R, Narayan SK. Progressive multifocal leukoencephalopathy in idiopathic CD4+ lymphocytopenia. J Neurovirol. 2018;24:526&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29687403</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R, San Jose Montano B. Cerebellar involvement in an immunocompetent patient presenting with progressive multifocal leukoencephalopathy. Case Rep Neurol Med. 2017;2017:2396068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5587930</ArticleId><ArticleId IdType="pubmed">28912987</ArticleId></ArticleIdList></Reference><Reference><Citation>Muino E, Rubio MA, Navalpotro I, et al. . Progressive multifocal leukoencephalopathy in an immunocompetent patient. Neurologia. 2017;32:337&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26617176</ArticleId></ArticleIdList></Reference><Reference><Citation>Nambirajan A, Suri V, Kataria V, et al. . Progressive multifocal leukoencephalopathy in a 44-year-old male with idiopathic CD4+ T-lymphocytopenia treated with mirtazapine and mefloquine. Neurol India. 2017;65:1061&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">28879898</ArticleId></ArticleIdList></Reference><Reference><Citation>Harel A, Horng S, Gustafson T, et al. . Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia. J Neurovirol. 2018;24:652&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29987583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano Y, Inoue H, Sakurai K, et al. . [Idiopathic CD4-positive lymphocytopenia-associated progressive multifocal leukoencephalopathy confirmed by brain biopsy following negative results of repeated CSF-JC-virus tests: a case report]. Rinsho shinkeigaku. 2018;58:750&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30487366</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal D, Tom JP, Chatterjee D, et al. . Progressive multifocal leukoencephalopathy in idiopathic CD4(+) lymphocytopenia: a case report and review of literature. Neuropathology. 2019;39:467&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">31584217</ArticleId></ArticleIdList></Reference><Reference><Citation>Krey L, Raab P, Sherzay R, et al. . Severe progressive multifocal leukoencephalopathy (PML) and spontaneous immune reconstitution inflammatory syndrome (IRIS) in an immunocompetent patient. Front Immunol. 2019;10:1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546850</ArticleId><ArticleId IdType="pubmed">31191548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartau M, Verkkoniemi-Ahola A, Paetau A, et al. . The incidence and predisposing factors of John Cunningham virus-induced progressive multifocal leukoencephalopathy in Southern Finland: a population-based study. Open Forum Infect Dis. 2019;6:ofz024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386113</ArticleId><ArticleId IdType="pubmed">30815501</ArticleId></ArticleIdList></Reference><Reference><Citation>Berciano J. Progressive multifocal leukoencephalopathy in an immunocompetent patient. Neurologia (Engl Ed). 2020;35:58.</Citation><ArticleIdList><ArticleId IdType="pubmed">28863831</ArticleId></ArticleIdList></Reference><Reference><Citation>Dato C, Elefante A, Coppola C, et al. . &#x201c;Borderline&#x201d; idiopathic CD4(+) T-cell lymphocytopenia presenting with atypical progressive multifocal leukoencephalopathy. J Neuroimmunol. 2020;349:577420.</Citation><ArticleIdList><ArticleId IdType="pubmed">33032014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hettipathirannahelage S, Wijetilleka S, Jewsbury H. Progressive multifocal leukoencephalopathy in a patient with occult hypogammaglobulinemia experiencing bilateral visual impairment. Eur J Ophthalmol. 2020;32:NP33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">33499658</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbach L, Bauer T, Ruber T, et al. . Treatment of progressive multifocal Leukoencephalopathy associated with idiopathic lymphocytopenia with Nivolumab. J Neurol Sci. 2021;427:117503.</Citation><ArticleIdList><ArticleId IdType="pubmed">34051624</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto T, Sakashita Y, Katada F, et al. . &#x201c;Burnt-out&#x201d; progressive multifocal leukoencephalopathy in idiopathic CD4(+) lymphocytopenia. Neuropathology. 2021;41:484&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34595780</ArticleId></ArticleIdList></Reference><Reference><Citation>Onwubiko IN, Taneja K, Gupta N, et al. . Unusual case of progressive multifocal leukoencephalopathy in a patient with Sjogren syndrome. Am J Forensic Med Pathol. 2021;42:186&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">33464755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamichi K, Miura Y, Shimokawa T, et al. . Nationwide laboratory surveillance of progressive multifocal leukoencephalopathy in Japan: Fiscal Years 2011-2020. Viruses. 2023;15:968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10144269</ArticleId><ArticleId IdType="pubmed">37112948</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton HB, Makley M, Slivka AP, et al. . Progressive multifocal leukoencephalopathy presenting as multiple enhancing lesions on MRI: case report and literature review. J Neuroimaging. 1995;5:125&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7718940</ArticleId></ArticleIdList></Reference><Reference><Citation>Boumaza X, Bonneau B, Roos-Weil D, et al. . Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. Ann Neurol. 2023;93:257&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10092874</ArticleId><ArticleId IdType="pubmed">36151879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortese I, Beck ES, Al-Louzi O, et al. . BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurol. 2021;20:639&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8395368</ArticleId><ArticleId IdType="pubmed">34302788</ArticleId></ArticleIdList></Reference><Reference><Citation>Lajaunie R, Mainardi I, Gasnault J, et al. . Outcome of progressive multifocal leukoencephalopathy treated by interleukin-7. Ann Neurol. 2022;91:496&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">35072281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>